Free Trial

Telomir Pharmaceuticals (TELO) Stock Price, News & Analysis

Telomir Pharmaceuticals logo
$1.48 -0.01 (-0.34%)
As of 03:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Telomir Pharmaceuticals Stock (NASDAQ:TELO)

Key Stats

Today's Range
$1.48
$2.07
50-Day Range
$1.13
$2.29
52-Week Range
$1.12
$8.40
Volume
61.95 million shs
Average Volume
1.75 million shs
Market Capitalization
$47.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Strong Buy

Company Overview

Telomir Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

TELO MarketRank™: 

Telomir Pharmaceuticals scored higher than 56% of companies evaluated by MarketBeat, and ranked 485th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Telomir Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Telomir Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Telomir Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Telomir Pharmaceuticals are expected to grow in the coming year, from ($0.40) to ($0.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Telomir Pharmaceuticals is -2.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Telomir Pharmaceuticals is -2.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Telomir Pharmaceuticals has a P/B Ratio of 152.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Telomir Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    9.22% of the float of Telomir Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Telomir Pharmaceuticals has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Telomir Pharmaceuticals has recently increased by 19.55%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Telomir Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Telomir Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.22% of the float of Telomir Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Telomir Pharmaceuticals has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Telomir Pharmaceuticals has recently increased by 19.55%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Telomir Pharmaceuticals has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Telomir Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    Only 4 people have searched for TELO on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Telomir Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
Receive TELO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Telomir Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TELO Stock News Headlines

TELO Makes Progress Toward Human Trials
“Sell Nvidia before earnings”
Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.tc pixel
Telomir Flat on Trial Data Release
TELO Announces Another Important Breakthrough
See More Headlines

TELO Stock Analysis - Frequently Asked Questions

Telomir Pharmaceuticals' stock was trading at $4.12 at the beginning of the year. Since then, TELO shares have decreased by 63.0% and is now trading at $1.5240.

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) released its quarterly earnings results on Thursday, August, 14th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.09.

Telomir Pharmaceuticals (TELO) raised $7 million in an initial public offering (IPO) on Friday, February 9th 2024. The company issued 1,000,000 shares at $7.00 per share. Kingswood Investments served as the underwriter for the IPO.

Telomir Pharmaceuticals' top institutional shareholders include Geode Capital Management LLC (0.66%), Marshall Wace LLP (0.25%), Y Intercept Hong Kong Ltd (0.22%) and Jane Street Group LLC (0.17%).

Shares of TELO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/14/2025
Today
8/28/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:TELO
Previous Symbol
NASDAQ:TELO
CIK
1971532
Fax
N/A
Employees
1
Year Founded
N/A

Price Target and Rating

High Price Target
$15.00
Low Price Target
$15.00
Potential Upside/Downside
+834.6%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.54)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$16.53 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-4,595.08%
Return on Assets
-1,750.91%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.39
Quick Ratio
2.39

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.01 per share
Price / Book
160.50

Miscellaneous

Outstanding Shares
32,280,000
Free Float
N/A
Market Cap
$51.81 million
Optionable
N/A
Beta
-0.67
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:TELO) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners